UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2019

 

OVID THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38085

46-5270895

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1460 Broadway, Suite 15044

New York, New York

 

10036

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646-661-7661

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock par value $0.001 per share

 

OVID

 

NASDAQ Global Select Market

 

 

Item 8.01. Other Events.

 

On June 18, 2019, Ovid Therapeutics Inc. (the “Company”) issued a Press Release announcing the Company to Host R&D Day on June 27, 2019. The program to feature regulatory and clinical program updates and presentations from thought leaders on Angelman syndrome, Fragile X syndrome, and rare developmental and epileptic encephalopathies (DEE).

 

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibit

 

Exhibit No.

  

Description

 

 

99.1

  

Press Release, dated June 18, 2019

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OVID THERAPEUTICS INC.

 

 

By:    

/s/ Thomas M. Perone

 

Thomas M. Perone

 

General Counsel & Corporate Secretary  

Dated: June 18, 2019

 

Exhibit 99.1

 

Ovid Therapeutics to Host R&D Day on June 27, 2019

 

Program to feature regulatory and clinical program updates and presentations from thought leaders on Angelman syndrome, Fragile X syndrome, and rare developmental and epileptic encephalopathies (DEE)

 

NEW YORK – June 18, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that it will host an R&D Day on Thursday, June 27, 2019 from 12:00 p.m. to 3:00 p.m. EDT in New York City. Members of Ovid’s senior management team will review the company’s current development programs and provide regulatory and clinical program updates. In addition, Ovid expects to outline key anticipated milestones and events for the second half of 2019.

 

Ovid’s R&D Day will also feature presentations and discussions from the following external clinician experts:

 

 

•

Cesar A. Ochoa-Lubinoff, MD, MPH, FAAP, Head, Division of Developmental-Behavioral Pediatrics, Rush Children's Hospital - Rush University Medical Center;

 

 

•

Alex Kolevzon, MD, Professor of Psychiatry and Pediatrics and Director, Child and Adolescent Psychiatry, Icahn School of Medicine at Mount Sinai; and

 

 

•

Daniel Tarquinio, DO, MS, Founder, Center for Rare Neurological Diseases in Norcross, GA.

 

A live audio webcast of the R&D Day can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com . An archived replay of the webcast will be available on the company's website for 90 days following the event.

 

Investors, equity research analysts and others interested in attending the event may contact Events.Ovid@burnsmc.com .

 

About Ovid Therapeutics

Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company's most advanced investigational medicine, OV101, is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing

V9

 

 

OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

 

For more information on Ovid, please visit http://www.ovidrx.com/.

 

Contacts

 

Investors and Media:

Ovid Therapeutics Inc.

Investor Relations & Public Relations

irpr@ovidrx.com

 

OR

 

Investors:

Alex Gray

Burns McClellan, Inc.

agray@burnsmc.com

(212) 213-0006